Reportedly, Walgreen Boots Alliance (WBA) has disclosed its plans to unveil its fourth-quarter financial results on October 12, 2023, at 7 a.m. ET, and immediately thereafter, a one-hour conference call with WBA management will commence at 8:30 a.m. ET.
A live broadcast of the conference call can be reached via the WBA investor relations website. Additionally, a replay of the call will be stored on the website for a duration of 12 months following the original event.
If you wish to access the replay, it will be open for listening from around 11:30 a.m. ET on October 12, 2023, until October 19, 2023. To listen to the replay, you can dial +1 800 770 2030 if you’re in the U.S. and Canada, or +1 647 362 9199 for international callers. Remember to use the replay code 8277955.
Walgreen Boots Alliance (WBA) is a pharmacy-led, health and well-being enterprise with a long history of trusted healthcare services, community pharmacy care, and pharmaceutical wholesaling dates. To learn more about Walgreen Boots Alliance (WBA) and to continue to track its progress please visit the Vista Partners Walgreens Boots Alliance Page.
Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.
DID YOU KNOW?….
Lantern Pharma (LTRN), an Artificial Intelligence (AI) firm that is transforming the cost, pace, and timeline of oncology drug discovery and development and specifically is developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, announced (on Sept. 18) that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for LP-284. LP-284 is being developed for the treatment of relapsed or refractory non-Hodgkin’s lymphoma (NHL), including mantle cell lymphoma (MCL) and double hit lymphoma (DHL) and other high-grade B-cell lymphomas (HGBL). Lantern expects to commence enrollment of patients for the first-in-human Phase 1 trial for LP-284 during the fourth quarter of 2023. Lantern estimates that LP-284 can have the potential to improve outcomes for 40,000 to 80,000 patients with blood cancers annually, with a global annual market potential of $4 Billion USD.
Panna Sharma is the President, CEO, and Board Member of Lantern Pharma Inc.
“This is now our second novel drug candidate to receive IND clearance from the FDA in the past 100 days, further validating our approach of leveraging AI and machine learning to accelerate the development of our pipeline. LP-284 holds blockbuster potential, and we have been able to expedite its journey from a concept to a first-in-human clinical trial in a highly efficient and cost-effective manner – less than 2.5 years and under approximately $2.7 million – underscoring the power and potential of our AI platform RADR® to accelerate oncology drug discovery and development. RADR® was used to unravel the mechanism of action of LP-284, prioritize its cancer indications, and generate machine-learning biomarker signatures that may be pivotal in selecting patients for future phases of the clinical trials. Our success-to-date with LP-284 reaffirms our commitment to harnessing the power of AI to transform cancer treatment and save lives,” stated Panna Sharma, Lantern’s President and CEO.
Learn more about Lantern Pharma (LTRN) by visiting our VP Watchlist pages.
